U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C31H48O2S2
Molecular Weight 516.842
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PROBUCOL

SMILES

CC(C)(SC1=CC(=C(O)C(=C1)C(C)(C)C)C(C)(C)C)SC2=CC(=C(O)C(=C2)C(C)(C)C)C(C)(C)C

InChI

InChIKey=FYPMFJGVHOHGLL-UHFFFAOYSA-N
InChI=1S/C31H48O2S2/c1-27(2,3)21-15-19(16-22(25(21)32)28(4,5)6)34-31(13,14)35-20-17-23(29(7,8)9)26(33)24(18-20)30(10,11)12/h15-18,32-33H,1-14H3

HIDE SMILES / InChI

Molecular Formula C31H48O2S2
Molecular Weight 516.842
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description

Probucol is used to lower levels of cholesterol (a fat-like substance) in the blood. Probucol is a drug used to lower LDL and HDL cholesterol yet has little effect on serum-triglyceride or VLDL cholesterol. This may help prevent medical problems caused by cholesterol clogging the blood vessels. Probucol was voluntarily removed from the market in the United States during 1995. The withdrawal from the market was due to safety concern. robucol lowers serum cholesterol by increasing the fractional rate of low-density lipoprotein (LDL) catabolism in the final metabolic pathway for cholesterol elimination from the body. Additionally, probucol may inhibit early stages of cholesterol biosynthesis and slightly inhibit dietary cholesterol absorption. Recent information suggests that probucol may inhibit the oxidation and tissue deposition of LDL cholesterol, thereby inhibiting atherogenesis. It appears to inhibits ABCA1-mediated cellular lipid efflux.

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LORELCO

Cmax

ValueDoseCo-administeredAnalytePopulation
1706 ng/mL
250 mg single, oral
PROBUCOL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
139400 ng × h/mL
250 mg single, oral
PROBUCOL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
177.5 h
250 mg single, oral
PROBUCOL plasma
Homo sapiens

Doses

AEs

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer







Drug as perpetrator​

Tox targets

PubMed

Sample Use Guides

In Vivo Use Guide
Adults: 500 milligrams two times a day taken with the morning and evening meals. Children: Up to 2 years of age—Use is not recommended. 2 years of age and over—Dose must be determined by your doctor.
Route of Administration: Oral
In Vitro Use Guide
Injured human umbilical vein endothelial cells (HUVECs) induced by Na2S2O4 served as an H/R model in vitro. The concentration of probucol in this study ranged from 3 to 27 μM. The results showed that the cell viability increased significantly with probucol, while the LDH leakage rate was significantly lower as analyzed by the LDH assay. Furthermore, the expression levels of GRP78, XBP-1, and CHOP were significantly downregulated.
Substance Class Chemical
Record UNII
P3CTH044XJ
Record Status Validated (UNII)
Record Version